




RealRate

PHARMACEUTICAL 2021

Karyopharm Therapeutics Inc.
Rank 290 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Karyopharm Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karyopharm Therapeutics Inc. compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 58% points. The greatest weakness of Karyopharm Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is -257%, being 98% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	276,531
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	60,203
Liabilities, Non-Current	11,285
Other Assets	34,300
Other Compr. Net Income	555
Other Expenses	3,014
Other Liabilities	191,016
Other Net Income	-24,114
Property and Equipment	2,219
Research and Development	150,813
Revenues	108,085
Selling, General and Administrative Expense	126,417

Output Variable	Value in 1000 USD
Assets	313,050
Liabilities	262,504
Expenses	280,244
Stockholders Equity	50,546
Net Income	-196,273
Comprehensive Net Income	-195,996
Economic Capital Ratio	-257%